Zhaolian Bian

Zhaolian Bian


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2017 in Journal of Infection
Verified
Journal Article
Open access
ZCZhi-Xian Chen
Zhi-Xian Chen
GGGui-Fang Gu
Gui-Fang Gu
ZBZhaolian Bian
Zhaolian Bian
WCWei-Hua Cai
Wei-Hua Cai
YSYi Shen
Yi Shen
GQGang Qin
Gang Qin
To determine the clinical course and perinatal transmission of chronic hepatitis B during pregnancy in a real life setting. A total of 221 singleton pregnant women with detectable HBV-DNA levels (≥103 copies/mL) were enrolled during January 2011 to June 2015. Forty-three high viraemic patients (≥106 copies/mL) received telbivudine in the 2nd or 3rd trimester according to their intention, while 89 high viraemic and 79 low viraemic (≥103 and <106 copies/mL) patients were the control cohorts. Primary endpoint was the pregnancy outcomes and secondary endpoint the perinatal transmission including intrauterine infection, immunoprophylaxis failure and occult infection. In all, 209 patients completed pregnancy with 209 infants, while 2 in telbivudine-treated cohort had unexplained late stillbirths. Twenty-nine (70.7%) of telbivudine-treated patients and 3 (3.4%) of untreated high viraemic controls achieved undetectable HBV-DNA levels prior delivery. At 7 months postpartum, immunoprophylaxis failure was significantly lower (2.4%) in telbivudine-treated cohort, compared with 16.9% and 10.1% in untreated high and low viraemic cohorts, respectively. Low viraemic patients may also need antiviral therapy since they bear moderate risk for perinatal transmission of HBV. However, more multicenter, large-scale studies are required before antepartum antiviral therapy is routinely recommended in patients with detectable viral loads.

7 March 2018 in Oncology Letters
Verified
Journal Article
Open access
PDF file
JSJian‑Dong Shen
Jian‑Dong Shen
SFShou‑Zhong Fu
Shou‑Zhong Fu
LJLin‑Ling Ju
Lin‑Ling Ju
YWYi‑Fang Wang
Yi‑Fang Wang
FDFeng Dai
Feng Dai
ZBZhaolian Bian
Zhaolian Bian
The present study aimed to illustrate the association of the expression of ubiquitin‑conjugating enzyme E2A (UBE2A) with the clinicopathological parameters and prognosis in hepatocellular carcinoma (HCC). The expression levels of UBE2A mRNA and protein in a total of 276 HCC tissues and six liver cell lines was detected by fluorescent quantitative polymerase chain reaction, western blotting and immunohistochemistry. Statistical analysis was also performed to assess the association of the expression of UBE2A with the clinicopathological parameters and prognosis by the GraphPad Prism and SPSS version 21.0 software. UBE2A mRNA and protein were highly expressed in HCC tissues compared with those in the adjacent normal tissue. Immunohistochemical analysis revealed that UBE2A protein was more strongly stained in the 276 paraffin‑embedded HCC tissues as compared with the 63 adjacent normal tissue. Statistical analysis also demonstrated that UBE2A expression was significantly associated with histological differentiation, TNM stage and vascular invasion of HCC (P<0.05). Notably, HCC patients with a high expression of UBE2A had a shorter survival time as compared with those with a low expression of UBE2A. There results suggested that UBE2A may be involved in the pathogenesis of HCC and may serve as an important prognostic marker. Further exploration of the involvement of UBE2A in HCC development may provide novel therapeutic targets.

21 February 2019 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
CGChengqi Guan
Chengqi Guan
ZLZhaoxiu Liu
Zhaoxiu Liu
CLCuihua Lu
Cuihua Lu
MXMingbing Xiao
Mingbing Xiao
HSHui Shi
Hui Shi
ZBZhaolian Bian
Zhaolian Bian

1 January 2018
Verified
Journal Article
Closed access
JSJian-Dong Shen
Jian-Dong Shen
XCXin-Feng Cai
Xin-Feng Cai
JWJue Wei
Jue Wei
CGChun-Yan Gu
Chun-Yan Gu
LJLin-Ling Ju
Lin-Ling Ju
LQLong-Ju Qi
Long-Ju Qi